Get access

PREGNANCY INTERRUPTION USING MIFEPRISTONE (RU-486): A New Choice for Women in the USA

Authors

  • Susan J. Mackenzie CNM, MS,

    Search for more papers by this author
    • Susan Mackenzie completed her Masters Degree in Science and Nurse-Midwifery studies at the University of Michigan in Ann Arbor, Michigan in 1996. She is currently practicing full scope nurse-midwifery in western Michigan. Before graduating as a CNM, Susan worked for 23 years as a registered nurse in the field of maternal and child health nursing.

  • Seonae Yeo RN, PhD

    Search for more papers by this author
    • Seonae Yeo is an assistant professor of parent-child nursing at the University of Michigan in Ann Arbor. Her research interest and activities are concentrated in maternal and child health, particularly in relation to exercise during the childbearing years and on promoting the success of student nurse practitioners and student nurse-midwives.


ABSTRACT

Mifepristone (RU-486) has recently been granted approval from the Food and Drug Administration for the early termination of pregnancy. Availability is anticipated during 1997. This article describes the pharmacologic function of mifepristone and discusses its potential clinical use in the United States, including its safety, efficacy, and possible complications.

Ancillary